RS57207B1 - Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti - Google Patents
Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonistiInfo
- Publication number
- RS57207B1 RS57207B1 RS20180568A RSP20180568A RS57207B1 RS 57207 B1 RS57207 B1 RS 57207B1 RS 20180568 A RS20180568 A RS 20180568A RS P20180568 A RSP20180568 A RS P20180568A RS 57207 B1 RS57207 B1 RS 57207B1
- Authority
- RS
- Serbia
- Prior art keywords
- sleep
- compound
- insomnia
- pharmaceutically acceptable
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505685P | 2011-07-08 | 2011-07-08 | |
| EP12735409.0A EP2729474B1 (en) | 2011-07-08 | 2012-07-02 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| PCT/US2012/045254 WO2013009517A1 (en) | 2011-07-08 | 2012-07-02 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS57207B1 true RS57207B1 (sr) | 2018-07-31 |
Family
ID=46513872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20180568A RS57207B1 (sr) | 2011-07-08 | 2012-07-02 | Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9481688B2 (enExample) |
| EP (1) | EP2729474B1 (enExample) |
| JP (1) | JP6050813B2 (enExample) |
| KR (1) | KR101582429B1 (enExample) |
| CN (1) | CN103703008B (enExample) |
| AU (1) | AU2012283035B2 (enExample) |
| BR (1) | BR112014000379A2 (enExample) |
| CA (1) | CA2840217C (enExample) |
| DK (1) | DK2729474T3 (enExample) |
| EA (1) | EA023460B1 (enExample) |
| ES (1) | ES2665035T3 (enExample) |
| HR (1) | HRP20180475T1 (enExample) |
| HU (1) | HUE037649T2 (enExample) |
| IN (1) | IN2014MN00144A (enExample) |
| LT (1) | LT2729474T (enExample) |
| MX (1) | MX341132B (enExample) |
| NO (1) | NO2729474T3 (enExample) |
| PL (1) | PL2729474T3 (enExample) |
| PT (1) | PT2729474T (enExample) |
| RS (1) | RS57207B1 (enExample) |
| SI (1) | SI2729474T1 (enExample) |
| WO (1) | WO2013009517A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2943498B1 (en) | 2013-01-14 | 2017-09-06 | Eli Lilly and Company | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists |
| TW201625644A (zh) | 2014-04-29 | 2016-07-16 | 美國禮來大藥廠 | 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN108371660B (zh) * | 2017-12-14 | 2020-03-10 | 五邑大学 | 一种四氢环戊二烯并吡咯化合物及其衍生物的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| BR0014447A (pt) * | 1999-09-29 | 2002-06-11 | Lilly Co Eli | Derivados de piperidina como inibidores da reabsorção |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
| CA2678897C (en) * | 2007-03-15 | 2015-10-20 | Aryx Therapeutics, Inc. | Dibenzo[b,f][1,4]oxazapine compounds |
| KR20110022631A (ko) * | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
| GB0910009D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxo Group Ltd | Novel compounds |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| LT2751115T (lt) * | 2011-08-30 | 2017-12-27 | Eli Lilly And Company | (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ilo junginiai, kaip dvigubo aktyvumo h1 atvirkštiniai agonistai/5-ht2a antagonistai |
-
2012
- 2012-07-02 PT PT127354090T patent/PT2729474T/pt unknown
- 2012-07-02 EA EA201391706A patent/EA023460B1/ru not_active IP Right Cessation
- 2012-07-02 NO NO12735409A patent/NO2729474T3/no unknown
- 2012-07-02 WO PCT/US2012/045254 patent/WO2013009517A1/en not_active Ceased
- 2012-07-02 KR KR1020147000119A patent/KR101582429B1/ko not_active Expired - Fee Related
- 2012-07-02 CA CA2840217A patent/CA2840217C/en not_active Expired - Fee Related
- 2012-07-02 LT LTEP12735409.0T patent/LT2729474T/lt unknown
- 2012-07-02 AU AU2012283035A patent/AU2012283035B2/en not_active Ceased
- 2012-07-02 JP JP2014519227A patent/JP6050813B2/ja active Active
- 2012-07-02 BR BR112014000379A patent/BR112014000379A2/pt not_active IP Right Cessation
- 2012-07-02 PL PL12735409T patent/PL2729474T3/pl unknown
- 2012-07-02 RS RS20180568A patent/RS57207B1/sr unknown
- 2012-07-02 DK DK12735409.0T patent/DK2729474T3/en active
- 2012-07-02 US US14/125,320 patent/US9481688B2/en active Active
- 2012-07-02 HR HRP20180475TT patent/HRP20180475T1/hr unknown
- 2012-07-02 SI SI201231263T patent/SI2729474T1/en unknown
- 2012-07-02 HU HUE12735409A patent/HUE037649T2/hu unknown
- 2012-07-02 CN CN201280031201.7A patent/CN103703008B/zh active Active
- 2012-07-02 MX MX2014000337A patent/MX341132B/es active IP Right Grant
- 2012-07-02 EP EP12735409.0A patent/EP2729474B1/en active Active
- 2012-07-02 ES ES12735409.0T patent/ES2665035T3/es active Active
-
2014
- 2014-01-23 IN IN144MUN2014 patent/IN2014MN00144A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2840217A1 (en) | 2013-01-17 |
| LT2729474T (lt) | 2018-05-10 |
| EP2729474B1 (en) | 2018-03-14 |
| HRP20180475T1 (hr) | 2018-06-15 |
| WO2013009517A1 (en) | 2013-01-17 |
| US9481688B2 (en) | 2016-11-01 |
| KR101582429B1 (ko) | 2016-01-04 |
| JP2014518280A (ja) | 2014-07-28 |
| ES2665035T3 (es) | 2018-04-24 |
| US20140121199A1 (en) | 2014-05-01 |
| EP2729474A1 (en) | 2014-05-14 |
| NO2729474T3 (enExample) | 2018-08-11 |
| EA023460B1 (ru) | 2016-06-30 |
| PL2729474T3 (pl) | 2018-08-31 |
| HUE037649T2 (hu) | 2018-09-28 |
| EA201391706A1 (ru) | 2014-04-30 |
| MX2014000337A (es) | 2014-11-13 |
| DK2729474T3 (en) | 2018-05-22 |
| PT2729474T (pt) | 2018-06-05 |
| CN103703008B (zh) | 2015-11-25 |
| JP6050813B2 (ja) | 2016-12-21 |
| AU2012283035B2 (en) | 2015-07-30 |
| IN2014MN00144A (enExample) | 2015-06-19 |
| CA2840217C (en) | 2016-03-22 |
| CN103703008A (zh) | 2014-04-02 |
| KR20140029512A (ko) | 2014-03-10 |
| AU2012283035A1 (en) | 2014-01-16 |
| SI2729474T1 (en) | 2018-04-30 |
| BR112014000379A2 (pt) | 2017-01-10 |
| MX341132B (es) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012300451B2 (en) | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT 2A antagonists | |
| RS57207B1 (sr) | Jedinjenja (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ila kao dvostruko delujući h1 inverzni agonisti/5-ht2a antagonisti | |
| KR101549315B1 (ko) | 이중 활성 H1 역 효능제/5-HT2A 길항제로서의 치환된 [(5H-피롤로[2,1-c][1,4]벤조디아제핀-11-일)피페라진-1-일]-2,2-디메틸프로판산 화합물 | |
| AU2014205616B2 (en) | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists |